Particle Health vs Redox: 3-Way TEFCA Guide 2026

Particle Health vs Redox for TEFCA USCDI exchange is a comparison of a clinical-data network path and an EHR integration fabric, not a new EHR and not a clearinghouse. TEFCA is the ONC Trusted Exchange Framework and Common Agreement for nationwide QHIN exchange, according to ONC TEFCA (2026). USCDI defines the data classes a TEFCA/QHIN query is expected to return, according to ONC USCDI (2026). This page is published from the homepage. Neither vendor paid for inclusion.

First QHIN designations: December 2023 according to the ONC TEFCA page already cited, which also states that becoming a QHIN typically takes about 12 months. You are buying a path onto that network-of-networks, or you are buying point-to-point EHR pipes. Those are different RFPs.

Office-based physicians using EHR: 78%+ according to HIMSS (2024) Health IT Adoption Report, used here as the batch primary for workflow integration — adoption is high; differentiation is whether USCDI actually lands in the chart. Payer FHIR API clock: January 1, 2027 according to CMS (2024) for CMS-0057-F Patient Access and Provider Access APIs. That is not this page's pair.

TL;DR: Choose Particle Health when the job is querying clinical records through a network/TEFCA-oriented API. Choose Redox when the job is connecting many EHRs with a normalized integration layer. Confirm QHIN participation on the contract; do not infer it from a homepage. Orchestrate only when a query result must wait for a clinician before it writes to the chart.

G2 Redox (2026) is the review neighborhood for the integration fabric. Particle Health's public site is the product evidence for the network query story. HL7 US Core is the FHIR implementation guide many USCDI payloads ride, according to HL7 US Core (2026).

TEFCA is a network; USCDI is the payload

TEFCA sets a universal floor so data can move beyond proprietary HIEs: treatment, payment, operations, public health, government benefits determination, and individual access, as listed on the ONC TEFCA page already cited. USCDI is the data-class list. HL7 US Core is how FHIR often carries those classes. Redox historically wins as iPaaS for EHR events. Particle historically wins as a query API for records.

Related care-ops: healthcare automation benchmarks, patient follow-up, appointment prep, and claims inquiry reduction. Those do not designate a QHIN.

Key Takeaways

• TEFCA is ONC's QHIN network-of-networks; USCDI is the data classes; US Core is a common FHIR IG.

• First QHINs were designated December 2023; QHIN onboarding is about 12 months.

• 78%+ EHR adoption means the bottleneck is exchange workflow, not "do we have an EHR."

• CMS-0057-F 2027 APIs are a different clock from this Particle vs Redox pair.

• Orchestrate chart writes only after a unique patient key and a clinician hold exist.

Who this Particle vs Redox page is for

This page is for digital-health product, interoperability, and health-system IT leads who need USCDI-class records in an app or EHR and who can store a patient identifier. Stack: EHR or app plus an exchange vendor plus a privacy officer. Pain: faxed records, one-off interfaces, or a TEFCA slide with no query in prod.

Red flags: you already have a live QHIN participant path returning USCDI into the chart with a clinician review; you are a cash-pay clinic with no exchange use case; you will not complete BAA/TPO paperwork or name a reviewer for inbound charts.

Weighted exchange criteria

Weights assume treatment or operations exchange, not a public-health reporting-only project.

TEFCA and FHIR matrix

Scores from public pages checked 2026-09-06: 2 = first-party exchange job; 1 = adjacent; 0 = not found. USTA = 1 hold, 1 recipe.

Particle wins network query positioning. Redox wins EHR integration fabric. Direct EHR APIs win if you only have one EHR and a staffed interface team. Confirm TEFCA/QHIN status on the edition you buy. USTA's 1s are a proposed query-and-chart hold.

Pricing and TCO for USCDI queries

Checked 2026-09-06. Particle Health and Redox are quote-led. Example: 8 clinics, 2,000 inbound record queries/month.

Ask for QHIN participant vs subparticipant path, per-query vs platform fees, and whether write-back is included. A cheaper interface that returns a PDF is not USCDI.

Particle Health and Redox profiles

Particle Health — best when the job is a records query network

Particle Health sells clinical data access via API, positioned for TEFCA/USCDI-class retrieval. Best fit: digital health and risk-bearing groups that query records rather than build 50 EHR interfaces. Limitations: confirm current QHIN path, use cases (treatment vs ops), and matching. Implementation: BAA, patient identity strategy, then a 10-patient pilot. Primary evidence: Particle public site. Disqualifier: you needed inbound ADT/orders from 12 EHRs more than a query API.

Redox — best when the job is many EHR pipes

Redox is an interoperability platform for sending and receiving clinical events across EHRs. Best fit: products that must subscribe to ADT, results, and similar events. Limitations: TEFCA is not automatic because you have an iPaaS; confirm. Implementation: Meta.DataModel mappings, then production monitoring. Primary evidence: Redox public pages and G2 Redox. Disqualifier: you only needed a nationwide query and will not staff per-EHR connections.

Direct EHR FHIR — best with one certified EHR and a team

If 78%+ of office physicians already have an EHR, your one-EHR shop may only need US Core on that EHR. Best fit: single instance, US Core IG, privacy review. Limitations: does not solve outside records. Disqualifier: patients arrive from everywhere.

When NOT to use US Tech Automations: if Particle or Redox already writes USCDI into the chart with a clinician review, do not add an orchestration layer. If you have no treatment relationship or HIPAA permission, do not query. If no clinician will accept inbound data, do not auto-file it.

Zapier, Make, or n8n can call an API, retry, and log. You still own minimum-necessary, patient matching, PHI retention, and the escalation when two MRNs collide. A proposed US Tech Automations design would require the clinician hold before chart write-back.

A proposed query-and-chart hold

An eight-clinic group running 2,000 queries a month, in a market where 78%+ of office physicians already use EHRs, can treat Redox Meta.DataModel (or FHIR Patient.id on a Particle query) as the object that must match the local MRN before write-back. The 8, 2,000, and 78% figures are a worked scenario; Meta.DataModel is a real Redox message metadata field.

US Tech Automations could, as a configurable capability, run the query, attempt a match, pause for a clinician when confidence is low, and emit a packet with USCDI classes returned and unmatched identifiers. Prerequisites: BAA, vendor API, local EMPI or MRN, human review before chart write. Not a live customer result.

A second proposed path: if the exchange purpose is not treatment, block the query. The agentic workflow layer is the allowlisted route for that hold.

Exchange-purpose glossary

• TEFCA: ONC Trusted Exchange Framework and Common Agreement.

• QHIN: Qualified Health Information Network; ~12-month designation path.

• USCDI: data classes for interoperability.

• US Core: HL7 FHIR IG for USCDI-oriented resources.

• RCE: Recognized Coordinating Entity (Sequoia Project under ONC contract).

• Exchange purpose: treatment, payment, operations, public health, benefits, IAS.

• iPaaS: integration fabric (Redox-style).

• EMPI: enterprise master patient index.

How to pilot ten patients without poisoning the chart

Pick ten patients with a treatment relationship and a local MRN. Query. Count USCDI classes returned, not pages in a PDF. Attempt a match. If two MRNs collide, stop write-back. A clinician hold is not bureaucracy; it is how you avoid filing the wrong problem list into the chart. Log the exchange purpose on every query. If the purpose is missing, the query should not run.

Particle vs Redox is not "which logo is on the TEFCA slide." It is whether you needed a nationwide query or fifty EHR event pipes. Write that sentence in the RFP. Confirm QHIN or participant language in the contract. Twelve months of QHIN onboarding is a calendar, not a weekend connector.

CMS-0057-F 2027 APIs can still matter to your payer team. They do not replace this pair. HL7 US Core still matters to how FHIR carries USCDI, as already cited above. G2 Redox is a review neighborhood, not a QHIN designation.

Export identifiers twice. If the vendor cannot export the patient keys you sent in, you cannot prove minimum-necessary later.

Interoperability RFPs fail when they mix three clocks. TEFCA/QHIN is ONC. USCDI is the payload list. CMS-0057-F is payer FHIR APIs on a 2027 build clock. Particle vs Redox is none of those clocks by itself. Particle is a query-shaped product. Redox is an event-pipe product. Write the use case as "I need outside records for treatment" or "I need ADT and results from twelve EHRs." If you write both, you may need both vendors, or you may need a QHIN participant plus an iPaaS — that is a budget, not a slogan.

Patient matching is the unglamorous half of USCDI. A perfect allergies section filed on the wrong MRN is harm. Require an EMPI or a documented match rule before write-back. Low-confidence matches wait. High-confidence matches can still wait if your clinicians asked them to. 78%+ EHR adoption means the receiving system exists; it does not mean it should auto-file.

Privacy review is a named person, not a checkbox on a BAA. Exchange purpose must be stored. Individual access services are not treatment. Payment and operations have different minimum-necessary stories. If your app cannot tag purpose, do not query.

If Particle or Redox already writes into the chart with a clinician review, stop shopping orchestration. If query results and local charts disagree on the person, the hold is the work.

G2 Redox listing year: 2026 according to G2 Redox (2026). Use it as a review neighborhood, then run ten patients. Count USCDI classes, match rate, write-backs after a clinician hold, and purpose tags. If Particle cannot show a written QHIN or participant path, treat TEFCA as a slide. If Redox cannot show the EHR events you actually need, treat iPaaS as a slide.

Interface staffing is the hidden TCO. A twelve-week implementation that needs a full-time analyst is not "the same as a query API." Budget the analyst. Budget the EMPI. Budget the privacy review. 78%+ EHR adoption does not pay those invoices. It only means the destination system exists.

Do not auto-file problem lists. Do not query without a purpose. Do not mix CMS-0057-F payer APIs into this RFP. Do not buy both vendors to paper over a missing match rule. Fix matching, then choose query or pipes.

Digital-health teams should write a one-page identity strategy before the first query: what is the local key, what is the inbound key, who merges duplicates, who un-merges a bad merge. Health-system IT should write a one-page event strategy before the first Redox feed: which events, which EHRs, which destination, which retry. Those two pages prevent a six-figure interface that files the wrong chart. Clinician review is not optional on low-confidence matches. Twelve-month QHIN onboarding is not a weekend. 2027 payer APIs are not this pair. Buy the path that matches the sentence you wrote in the RFP, then hold the chart write until a person says the patient is the same person.

Vendors will try to collapse query, iPaaS, and QHIN into one slide. Keep them apart in the contract. A Particle-style query API that returns USCDI classes for treatment is one SOW. A Redox-style ADT feed from named EHRs is a second SOW. A QHIN participant path with a 12-month designation story is a third SOW. If the paper mixes them, you will pay for all three and go live on none. Staff the match rule first. Staff the clinician hold second. Buy the pipe third. That order is how 78%+ EHR adoption becomes usable data instead of another PDF inbox. Privacy review signs the purpose tag. Interface analysts own retries. Nobody owns a silent write-back. If that sentence is controversial in your org, you are not ready to query production patients. Put the match rule, the purpose tag, and the clinician hold in the SOW as acceptance tests, not as a future phase. A future phase is how USCDI becomes another unread PDF. Acceptance tests that mention Patient.id, Meta.DataModel, and a named clinician are boring on purpose. Boring is how charts stay attached to the right person. If a vendor calls that bureaucracy, they are selling a slide, not an exchange path you can staff. Staff the slide last. Staff the match first.

FAQs

Is Particle a QHIN?

QHIN status is a designation process of about 12 months. Confirm Particle's current participant/QHIN path on the contract. Do not infer it from marketing.

Is Redox TEFCA?

Redox is an integration platform. TEFCA connectivity is a separate fact. Ask for the QHIN or participant path in writing.

Does CMS-0057-F replace TEFCA?

No. CMS-0057-F is a payer FHIR API clock (generally 2027 for APIs). TEFCA is ONC QHIN exchange. Adjacent, not the same RFP.

Why does 78%+ EHR adoption matter?

If most offices already have an EHR, buying another EHR does not move USCDI. Buying a query or interface path might.

When is Zapier enough?

When you are moving non-PHI status flags with retries. When a chart can be overwritten, add a clinician hold.

How should US Tech Automations sit on Redox?

US Tech Automations should not become the HIE. A proposed path holds write-back until Meta.DataModel payloads match a local Patient.id. See pricing for how that hold is scoped.